The short version of HPLC-UV fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-05-14 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
In the first seven years of the reign of Juan Carlos I, the transition to democracy was completed, making Spain the only non-communist dictatorship left in Europe. The Spanish transition, of which the end is usually placed in the victory of the PSOE in the October 1982 elections, is part of the third "democratizing wave" of the 20th century, which began in Portugal in 1974 with the "Carnation Revolution" and ended with the fall of the Berlin Wall in 1989.
== History == The Celloscope was developed for the Swedish company AB Lars Ljungberg & Co under the direction of engineer Erik Öhlin at Linson Instrument AB. In an interview published in the Clinical Biochemistry in the Nordics, a membership magazine for the Nordic Association for Clinical Chemistry, Lars Ljungberg explains that he and his coworkers had been considering different solutions for counting blood cells for some time when they came across a method presented by the American Navy on how particles could be counted when allowed to pass a capillary hole through which a weak direct current was passed simultaneously. The Celloscope method exploits the feature of blood cells not being conductive and therefore make interruptions (pulses) to the current, which then can be counted. What Ljungberg and coworkers did not know was that Wallace H. Coulter in Chicago had applied for and received a patent on the particle count principle in 1953. When presented at a German tradeshow in September 1957, the Celloscope counter was examined by Dr. George Brecher, the first author of one of the NIH evaluations of the Coulter counter. In a letter to Coulter, Brecher reported about what he thought was a close functional copy of the Coulter counter, yet with simpler electronics and an integrated sample stand, creating a both smaller and less costly instrument for use in clinical applications. When the Celloscope was introduced to the market in the early 60s, a lawsuit was filed by Coulter Electronics Inc. against AB Lars Ljungberg & Co for alleged infringement of the American patent.
== Description == Most Scutellaria are annual or perennial herbaceous plants from 5 to 100 cm (2 to 39 in) tall, however a few are subshrubs. Some Scutellaria are aquatic. Scutellaria have four-angled stems and opposite leaves, and flowers with upper and lower lips. The genus is most easily recognized by the typical shield on the calyx that has also prompted its common name.
Sources: en.wikipedia.org
Botha wanted all the Cuban military personnel to be withdrawn, and over a period of twelve months rather than three years. He also countered that the Namibian independence process could only take place once the Cuban withdrawal was initiated. The Lusaka Accords were abandoned in the wake of Operation Argon, a failed sabotage mission carried out by South African special forces in Angola's oil-rich Cabinda exclave. Four years of military escalation and massive defence expenditures had a drastic impact on Angola's state finances, which were only being balanced by petroleum revenue. The largest oil refinery in the country was located on the Cabindan coast and operated by a US firm, Gulf Oil, under the auspices of the Cabina-Gulf Oil National Petroleum Company of Angola (SONAGOL). By 1984 Gulf had invested over 1.3 billion dollars in its Cabinda operation, which was exporting 165,495 barrels of oil per day. At the time, the revenue from the Gulf refinery generated 90% of Angola's foreign exchange. The Reagan administration separated its political positions on Angola from its position on SONAGOL, with Crocker hoping that American multinational companies in general, and Gulf in particular, would be a moderating force on the Marxist government. South Africa had noted the critical importance of the refinery's contribution to the FAPLA war effort and had begun investigating ways to disrupt it without incurring the ire of the US, which would have to react if American commercial interests were threatened.
The plant is stemless and usually produces several rosettes consisting of wiry, lax, grasslike, flattened leaves. Leaves, up to 1 meter long and 12mm wide (3+1⁄3 feet x ~1⁄2 inch), have margins bearing many small, close-together, skin-cutting teeth. Inflorescences are panicle type and up to 35cm long (~14 inches) atop scapes up to 70cm tall (~2+1⁄3 feet) Flowers are functionally male or female, the males with larger stamens, the females with better developed pistils, but both types have both stamens and pistils. Flowers have six yellow-green tepals up to 2.5mm long (~2+1⁄3 inch) Fruits are winged, slightly inflated capsules up to 10 mm tall and 11mm wide (~1⁄3 inch).
== Advantages == APPI is most used for LC/MS although it has recently found widespread use in ambient applications such as detection of explosives and narcotics compounds for security applications using ion mobility spectrometry. Compared to the more commonly used predecessor ionization sources ESI and APCI, APPI ionizes a broader range of compounds with the benefit increasing toward the non-polar end of the scale. It also has relatively low susceptibility to ion suppression and matrix effects, which makes APPI very effective in detecting compounds quantitatively in complex matrices. APPI has other advantages including a broader linear range and dynamic range than ESI as seen by the example in the left figure. It is also generally more selective than APCI with reduced background ion signals as shown in the right figure. This latter example also highlights the benefit of APPI vs. ESI in that the HPLC conditions were for non-polar normal-phase in this case using n-hexane solvent. ESI requires polar solvents and further hexane could pose an ignition hazard for ESI and APCI that use high voltages. APPI works well under normal-phase conditions since many of the solvents are photoionizable and serve as dopant ions, which allows specialized applications such as separation of enantiomers (right figure).
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.